Bead BioPharma has emerged from stealth by submitting a patent for a novel cancer drug platform. The life sciences company, backed by Archangels, submitted the patent in efforts to launch its formal entry into one of the most competitive sectors of global oncology. Bead BioPharma is focused on antibody-drug conjugates (ADCs), a class of cancer therapies sometimes described as ‘guided missiles’, which are […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!